Filing Flows › Comparisons › CELU vs AVBP
Celularity vs ArriVent BioPharma: CELU and AVBP compared
Celularity is the larger company: $5.4M of revenue in its latest quarter (Q2 2026) against $5.0M for ArriVent BioPharma (Q3 2026). Celularity is more profitable, with an operating margin of -78.0% against -867.5%.
Where the money goes: CELU and AVBP
Celularity (CELU) · Q2 2026
Celularity, Q2 2026: revenue $5.4M (-5% year over year), operating margin -78.0%, net earnings $706K, operating cash flow −$1.1M. The chart follows the revenue to costs, profit and cash.
ArriVent BioPharma (AVBP) · Q3 2026
ArriVent BioPharma, Q3 2026: revenue $5.0M, operating margin -867.5%, net loss $40.3M, operating cash flow −$40.7M. The chart follows the revenue to costs, profit and cash.
| Celularity (CELU) | ArriVent BioPharma (AVBP) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $5.4M | $5.0M |
| Revenue growth, Y/Y | -5% | — |
| Operating margin | -78.0% | -867.5% |
| Net earnings | $706K | −$40.3M |
| Net margin | 13.0% | -806.3% |
| Operating cash flow | −$1.1M | −$40.7M |
Where the revenue comes from
Celularity
- Product: $4.1M (75%)
- License Royalty and Other: $719K (13%)
- Service: $652K (12%)
Questions
Which is bigger, Celularity or ArriVent BioPharma?
Celularity is the larger company: $5.4M of revenue in its latest quarter (Q2 2026) against $5.0M for ArriVent BioPharma (Q3 2026).
Is Celularity or ArriVent BioPharma growing faster?
Celularity is more profitable, with an operating margin of -78.0% against -867.5%.
More: Celularity earnings · how Celularity makes money · ArriVent BioPharma earnings · how ArriVent BioPharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 20, 2026; 10-Q filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.